Literature DB >> 6166569

Inhibition of human herpesviruses by combination of acyclovir and human leukocyte interferon.

M J Levin, P L Leary.   

Abstract

Human leukocytes interferon in low concentrations (1 to 5 U/ml) enhanced the antiviral effect of acyclovir against herpes simplex virus, varicella-zoster virus, and cytomegalovirus grown in human fibroblasts. This occurred without additive inhibition of the division of human fibroblasts or proliferation of peripheral blood mononuclear cells. The combined antiviral effect was additive against clinical isolates of cytomegalovirus and was synergistic against clinical isolates of the other two viruses. The magnitude of the effect with cytomegalovirus was the same when laboratory and wild-type virus were compared. The persistence of varicella-zoster virus in the presence of acyclovir in infected human cells was also reduced by the addition of interferon.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6166569      PMCID: PMC351549          DOI: 10.1128/iai.32.3.995-999.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  10 in total

1.  Inhibition of Herpesvirus hominis replication by human interferon.

Authors:  L Rasmussen; L B Farley
Journal:  Infect Immun       Date:  1975-07       Impact factor: 3.441

2.  Proliferative and interferon responses by peripheral blood mononuclear cells after bone marrow transplantation in humans.

Authors:  M J Levin; R Parkman; M N Oxman; J M Rappeport; M Simpson; P L Leary
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

3.  Varicella zoster virus: interferon production and comparative interferon sensitivity in human cell cultures.

Authors:  R W Armstrong; T C Merigan
Journal:  J Gen Virol       Date:  1971-07       Impact factor: 3.891

4.  Production of high-titered interferon in cultures of human diploid cells.

Authors:  E A Havell; J Vilcek
Journal:  Antimicrob Agents Chemother       Date:  1972-12       Impact factor: 5.191

5.  A method for testing for synergy with any number of agents.

Authors:  M C Berenbaum
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

6.  Growth inhibition by acycloguanosine of herpesviruses isolated from human infections.

Authors:  C S Crumpacker; L E Schnipper; J A Zaia; M J Levin
Journal:  Antimicrob Agents Chemother       Date:  1979-05       Impact factor: 5.191

7.  Acyclovir kinetics after intravenous infusion.

Authors:  P de Miranda; R J Whitley; M R Blum; R E Keeney; N Barton; D M Cocchetto; S Good; G P Hemstreet; L E Kirk; D A Page; G B Elion
Journal:  Clin Pharmacol Ther       Date:  1979-12       Impact factor: 6.875

8.  Toxicity and efficacy of human leukocyte interferon for treatment of cytomegalovirus pneumonia after marrow transplantation.

Authors:  J D Meyers; R W McGuffin; P E Neiman; J W Singer; E D Thomas
Journal:  J Infect Dis       Date:  1980-05       Impact factor: 5.226

9.  Effect of acyclovir on the proliferation of human fibroblasts and peripheral blood mononuclear cells.

Authors:  M J Levin; P L Leary; R D Arbeit
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

10.  Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma.

Authors:  J U Gutterman; G R Blumenschein; R Alexanian; H Y Yap; A U Buzdar; F Cabanillas; G N Hortobagyi; E M Hersh; S L Rasmussen; M Harmon; M Kramer; S Pestka
Journal:  Ann Intern Med       Date:  1980-09       Impact factor: 25.391

  10 in total
  28 in total

1.  Nucleoside metabolism in herpes simplex virus-infected cells following treatment with interferon and acyclovir, a possible mechanism of synergistic antiviral activity.

Authors:  W J O'Brien; E C Coe; J L Taylor
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Biosynthetic human interferon treatment of herpetic keratitis.

Authors:  G Smolin
Journal:  Trans Am Ophthalmol Soc       Date:  1983

3.  Synergistic antiviral effects of antiherpes compounds and human leukocyte interferon on varicella-zoster virus in vitro.

Authors:  M Baba; M Ito; S Shigeta; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

4.  Susceptibility of vaccine strains of varicella-zoster virus to antiviral compounds.

Authors:  S R Preblud; A M Arbeter; E A Proctor; S E Starr; S A Plotkin
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

5.  Sensitivity in vitro of herpes simplex virus isolates to human fibroblast interferon.

Authors:  S Leventon-Kriss; M Movshovitz; Z Smetana; M Shewach-Millet; T Doerner; T Gotlieb-Stematsky
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

6.  Synergistic therapy by acyclovir and A1110U for mice orofacially infected with herpes simplex viruses.

Authors:  M N Ellis; D C Lobe; T Spector
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

7.  Acyclovir monotherapy versus acyclovir plus beta-interferon in focal viral encephalitis in children.

Authors:  U Wintergerst; B H Belohradsky
Journal:  Infection       Date:  1992 Jul-Aug       Impact factor: 3.553

8.  Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with beta-interferon against herpes simplex virus type 2 in mice.

Authors:  E B Fraser-Smith; D A Eppstein; Y V Marsh; T R Matthews
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

9.  Inhibition of human cytomegalovirus replication by 9-(1,3-dihydroxy-2-propoxymethyl)guanine alone and in combination with human interferons.

Authors:  L Rasmussen; P T Chen; J G Mullenax; T C Merigan
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

10.  Effect of acyclovir and interferon on human hematopoietic progenitor cells.

Authors:  L M Parker; J M Lipton; N Binder; E L Crawford; M Kudisch; M J Levin
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.